Nature's Sunshine Products (NATR) Earnings Date & Reports

Key Takeaways

• Q3 2026 net sales declined 9.1% year over year to $116.6 million, missing analyst consensus of roughly $129.5 million.
• Adjusted earnings per share (EPS) of $0.14 fell well short of the $0.25 consensus estimate, while GAAP diluted EPS dropped to $0.11 from $0.30 a year earlier.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) fell to approximately $11.1 million from $15.2 million in the prior-year quarter.
• Management lowered full-year 2026 guidance to net sales of $460–$470 million and adjusted EBITDA of $44–$48 million, down from its prior ranges.
• The company cited operational disruptions in China, ongoing weakness in Taiwan, and a normalization in its North America digital business as key drivers.
• The balance sheet remains debt-free, with $89.4 million in cash and cash equivalents at quarter-end.
• For more context, explore Nature's Sunshine's Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages.
• Looking for automated trade ideas? Explore Tickeron's Trending AI Robots to see how AI-driven strategies are scanning the market.

Earnings Context and Why It Matters

Nature's Sunshine Products, Inc. (Nasdaq: NATR) is a global manufacturer and distributor of nutritional and personal care products, operating across Asia, Europe, North America, and Latin America. The company entered 2026 with strong momentum, reporting record first-quarter sales and continued expansion of its digital and subscription autoship channels. That backdrop made the third-quarter print especially significant: investors were watching whether the growth engine could be sustained across regions, and whether elevated gross margins and a debt-free balance sheet could be maintained. The quarter matters because it tests the credibility of management's "Vision for Growth" strategy, which targets doubling the business to $1 billion in sales over time. A stumble here raises questions about the durability of recent momentum.

Reported Results

For the third quarter ended September 30, 2026, Nature's Sunshine reported net sales of $116.6 million, down 9.1% from $128.3 million a year earlier and below the consensus estimate of approximately $129.5 million. GAAP (Generally Accepted Accounting Principles) diluted EPS came in at $0.11, compared with $0.30 in the prior-year period. On an adjusted basis, EPS of $0.14 missed the $0.25 consensus expectation by a wide margin.

Adjusted EBITDA declined to roughly $11.1 million from $15.2 million in Q3 2025, while operating margin contracted to 4.5% from 7.0% a year ago. Selling, general, and administrative (SG&A) expenses decreased to $42.3 million from $45.7 million, reflecting disciplined cost management amid softer sales. On the balance sheet, the company ended the quarter with $89.4 million in cash and cash equivalents and no debt, and it repurchased 232,000 shares for approximately $3.5 million.

Management pointed to three primary headwinds: continued year-over-year declines in China, where operational disruptions weighed on its consultant leadership base; ongoing weakness in Taiwan; and more normalized comparisons in the North America digital business after several quarters of exceptional growth.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors tracking the health and wellness sector or monitoring names like NATR after an earnings event, the AI Screener offers a structured way to surface fresh opportunities as market conditions shift.

Market Reaction and Investor Sentiment

Investor reaction to the report was sharply negative. Shares of NATR dropped roughly 13.3% to around $11.13 immediately following the release, according to market data, as the revenue miss and reduced full-year outlook overshadowed the company's still-strong balance sheet. The magnitude of the miss, particularly in adjusted EPS and the lowered guidance midpoint, signaled to investors that the challenges in China and the digital business were more persistent than previously communicated.

Sentiment had been building through the first half of 2026 on the back of digital growth and record quarterly sales, but the third-quarter reset reminded the market of the inherent volatility in direct-selling and regionally concentrated revenue. The stock's decline reflects a repricing of near-term growth expectations rather than a reassessment of the company's long-term strategic direction.

Forward Outlook and Key Factors to Monitor

Looking ahead, management now expects full-year 2026 net sales of $460–$470 million and adjusted EBITDA of $44–$48 million, a meaningful reduction from the $490–$500 million and $48–$52 million ranges issued in August. For the fourth quarter, the company anticipates gross margin in the low 72% range, slightly below the prior year due to unfavorable foreign exchange.

Investors should watch several catalysts over the coming quarters. First is China: management has acknowledged that operational disruptions damaged its consultant leadership base, which it has begun rebuilding, but expects challenges there to continue into 2027. Second is the North America digital business, where comparisons are normalizing after several quarters of outsized growth; sustaining customer acquisition and subscription autoship adoption will be critical.

Additionally, the company is preparing several growth initiatives under its "Vision for Growth" plan, including the launch of a women's health product across Asia, a reimagined U.S. direct-selling program expected by mid-2027, expansion in Germany and Japan, and potential entry into another Asian market pending licensing approval. Management has also signaled an openness to mergers and acquisitions (M&A) to accelerate toward its $1 billion sales goal, though timing remains uncertain. With no debt and a solid cash position, the company retains financial flexibility to execute these plans even as near-term results face pressure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations